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SUMMARY
To estimate an overall treatment difference with data from a randomized, comparative clinical study,
baseline covariates are often utilized to increase the estimation precision. Using the standard analysis of
covariance (ANCOVA) technique for making inferences about such an average treatment difference may
not be appropriate, especially when the fitted model is non-linear. On the other hand, the novel augmen-
tation procedure recently studied, for example, by Zhang, Davidian and Tsiatis (2008) is quite flexible.
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2 L. TIAN ET AL.
However, in general, it is not clear how to select covariates for augmentation effectively (Shao et al, 2010).
An overly adjusted estimator can be severely biased. Furthermore, the results from the standard inference
procedure by ignoring the sampling variation from the variable selection process may not be valid. In this
paper, we first propose an estimation procedure, which augments the simple treatment contrast estimator
directly with covariates. The new proposal is asymptotically equivalent to the aforementioned augmenta-
tion method. To select covariates, we utilize the standard lasso procedure. Furthermore, to avoid potential
bias of the resulting lasso-type estimator, a cross validation method is used to obtain our final estimation
procedure. The validity of the new proposal is justified theoretically and empirically. We illustrate the
procedure extensively with a well-known primary biliary cirrhosis clinical trial data set.
Keywords: ANCOVA; Cross validation; Efficiency augmentation; Mayo PBC data; Semi-parametric efficiency
1. INTRODUCTION
For a typical randomized clinical trial to compare two treatments, generally a summary measure 0 for
quantifying the treatment effectiveness difference can be estimated unbiasedly or consistently using its
simple two-sample empirical counterpart, say ^. With the subject’s baseline covariates, one may obtain
a more efficient estimator for 0 via a standard analysis of covariance (ANCOVA) technique or a novel
augmentation procedure, which is well documented in Zhang, Tsiatis and Davidian (2008) and a series of
papers (Leon et al. 2003, Tsiatis 2006, Tsiatis et al. 2008, Lu & Tsiatis 2008, Gilbert et al. 2009, Zhang
& Gilbert 2010). The ANCOVA approach can be problematic, especially when the regression model is
non-linear, for example, the logistic or Cox model. For this case, the ANCOVA estimator generally does
not converge to 0; but to a quantity which may be difficult to interpret as a treatment contrast measure.
Moreover, in the presence of censored event time observations, this quantity may depend on the censoring
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distribution. On the other hand, the above augmentation procedure, referred as ZTD in the literature always
produces a consistent estimator for 0; provided that the simple estimator ^ is consistent.
In theory, the ZTD estimator is asymptotically more efficient than ^ no matter how many covariates
being augmented. However, in practice, the penalty of an overly augmented estimator can be quite severe.
That is, the resulting estimator can be non-trivially biased or its standard error may be larger than that of
^. Recently Zhang et al. (2008) showed empirically that the ZTD via the standard stepwise regression for
variable selection performs satisfactorily when the number of covariates is not large. In general, however,
it is not clear that the standard inference procedures for 0 based on estimators augmented by covariates
selected via a rather complex variable selection process is appropriate especially when the number of
covariates involved is not small relative to the sample size. Therefore, it is highly desirable to develop an
estimation procedure to properly and systematically augment ^ and make valid inference for the treatment
difference based on studies with practical sample sizes.
Now, let Y be the response variable, T be the binary treatment indicator and Z be a p dimensional
vector of covariates or a function thereof including the intercept. The data, f(Yi; Ti;Zi); i = 1;    ; ng;
consist of n independent copies of (Y; T;Z), where T and Z are independent of each other. Let P (T =
1) =  2 (0; 1). First, suppose that we are interested in the mean difference: 0 = E(Y jT = 1)  
E(Y jT = 0). A simple unadjusted estimator is
^ =
1
n
nX
i=1
(Ti   )Yi
(1  ) ;
which consistently estimates 0. To improve efficiency in estimating 0, one may employee the standard
ANCOVA procedure by fitting the following linear regression working model:
E(Y jT;Z) = T + 0Z;
Hosted by The Berkeley Electronic Press
4 L. TIAN ET AL.
where  and  are unknown parameters. Since T ? Z and f(Ti;Zi); i = 1;    ; ng are independent
copies of (T;Z), the resulting ANCOVA estimator is asymptotically equivalent to
^   ^0
(
1
n
nX
i=1
(Ti   )Zi
(1  )
)
; (1.1)
where ^ is the ordinary least square estimator for  of the model E(Y jZ) = 0Z. The ^ converges to
0 = argminE(Y   0Z)2;
as n!1. It follows that the ANCOVA estimator is asymptotically equivalent to
^   00
(
1
n
nX
i=1
(Ti   )Zi
(1  )
)
. (1.2)
In theory, since ^ is consistent to 0, the ANCOVA estimator is also consistent to 0 and more efficient
than ^ regardless of whether the above working model is correctly specified. Note that the nonparametric
ANCOVA estimator proposed by Koch et al. (1998) and ZTD estimator are also asymptotically equivalent
to (1.2), which was noted by Tsiatis et al. (2008). We give details of this equivalence in Appendix A.
The novel ZTD procedure is derived by specifying optimal estimating functions under a very general
semi-parametric setting. The efficiency gain from the ZTD has been elegantly justified using the semi-
parametric inference theory (Tsiatis 2006). The ZTD is much more flexible than the ANCOVA method
in that it can handle cases when the summary measure 0 is beyond the simple difference of two group
means. On the other hand, the ANCOVA method may only work under the above simple linear regression
model.
In this paper, we study the estimator (1.1), which augments ^ directly with the covariates. The key
question is how to choose ^ in (1.1) especially when p is not small with respect to n. Here, we utilize
the lasso procedure with a cross validation process to construct a systematic procedure for selecting co-
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variates to increase the estimation precision. The validity of the new proposal is justified theoretically and
empirically via an extensive simulation study. The proposal is also illustrated with the data from a clinical
trial to evaluate a treatment for a specific liver disease.
2. ESTIMATING THE TREATMENT DIFFERENCE VIA PROPER AUGMENTATION FROM COVARIATES
For a general treatment contrast measure 0 and its simple two sample estimator ^, assume that
^   0 = n 1
nX
i=1
i() + op(
1p
n
);
where i() is the influence function from the ith observation,  is a vector of unknown parameters, and
i = 1;    ; n. Note that the influence function generally only involves a rather small number of unknown
parameters, which is not dependent on Z. Let ^ denote the consistent estimator for . Generally, the above
asymptotic expansion is also valid with i being replaced by i(^). Now, (1.2) can be rewritten as
^   00
 
n 1
nX
i=1
i
!
;
where i = (Ti   )Zi=f(1  )g; i = 1;    ; n. Then ^ in (1.1) is the minimizer of
nX
i=1
(i(^)  0i)2. (2.1)
When the dimension of Z is not small, to obtain a stable minimizer, one may consider the following
regularized minimand:
L() =
nX
i=1
(i(^)  0i)2 + jj;
where  is the lasso tuning parameter (Tibshirani 1996) and j  j denote the L1 norm for a vector. For any
fixed ; let the resulting minimizer be denoted by ^(). The corresponding augmented estimator and its
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variance estimator are
^lasso() = ^   ^()0
 
n 1
nX
i=1
i
!
and
V^lasso() = n
 2
nX
i=1
fi(^)  ^()0ig2; (2.2)
respectively. When the dimension of Z is small relative to the sample size, one may ignore the variability
of ^() and treat it as a constant when we make inferences about 0. In general, however, for practical
sample sizes, ^lasso() can be substantially biased partly due to the fact that ^() and fi; i = 1;    ; ng
are correlated. In Appendix B we show via a simple example this undesirable feature of the above estima-
tion procedure.
One possible solution to solve the above problem is to reduce the correlation between ^() and i
using a cross validation procedure. Specifically, we randomly split the data into K non-overlapping sets
fD1;    ;DKg and construct an estimator for 0 :
^cv() = ^   1
n
nX
i=1
^( i)()0i;
where i 2 Dki , ^( i)() is the minimizer of
X
j =2Dki
(j(^( i))  0j)2 + jj;
and ^( i) is a consistent estimator for  with all data, but not from Dki . Note that ^( i)() and i are
independent and no extra bias would be added from ^cv() to ^. When n  p, the variance of ^cv()
can be estimated by V^lasso() given in (2.2). However V^lasso() tends to underestimate its true variance
when p is not small.
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Here, we utilize the above cross validation procedure to construct a natural variance estimator:
V^cv() = n
 2
nX
i=1
fi(^( i))  ^0( i)()ig2.
In Appendix C, we justify that this estimator is better than V^lasso(). Moreover, when  is close to zero
and p is large, that is, one almost uses the standard least square procedure to obtain ^( i)(); the above
variance estimate can be modified slightly for improving its estimation accuracy (see Appendix C for
details). A natural “optimal” estimator using the above lasso procedure is ^opt = ^cv(^); where ^ is the
penalty parameter value, which minimizes V^cv() over a range of  values of interest.
3. APPLICATIONS
In this section, we show how to apply the new estimation procedure to various cases. To this end, we
only need to determine the initial estimate ^ for the contrast measure of interest and its corresponding first
order expansion in each application. Firstly, we consider the case that the response is continuous or binary
and the group mean difference is the parameter of interest. Here
^ =
1
n
nX
i=1
(Ti   )Yi
(1  ) .
In this case, it is straightforward to show that
^   0 = 1
n
nX
i=1

Ti(Yi   ^1)

  (1  Ti)(Yi   ^0)
1  

+ op(
1p
n
);
where  = (1; 0)0, ^1 =
Pn
i=1 TiYi=n; and ^0 =
Pn
i=1(1  Ti)Yi=(1  )n.
Now, when the response is binary with success rate pj for the treatment group j; j = 0; 1; but 0 =
logfp1(1  p0)=p0=(1  p1)g; then
^ = log(p^1)  log(1  p^1)  log(p^0) + log(1  p^0);
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where p^1 =
Pn
i=1 TiYi=n; and p^0 =
Pn
i=1(1  Ti)Yi=(1  )n. For this case,
^   0 = 1
n
nX
i=1

(Yi   p^1)Ti
p^1(1  p^1)  
(Yi   p^0)(1  Ti)
(1  )p^0(1  p^0)

+ op(
1p
n
).
Lastly, we consider the case when Y is the time to a specific event, but may be censored by an
independent censoring variable. To be specific, we observe ( ~Y ;) where ~Y = Y ^ C;  = I(Y < C);
C is the censoring time and I() is the indicator function. A most commonly used summary measure
for quantifying the treatment difference in survival analysis is the ratio of two hazard functions. The
two sample Cox estimator is often used to estimate such a ratio. However, when the proportional hazards
assumption between two groups is not valid, this estimator converges to a parameter which may be difficult
to interpret as a measure of the treatment difference. Moreover, this parameter depends on the censoring
distribution. Therefore, it is desirable to use a model-free summary measure for the treatment contrast.
One may simply use the survival probability at a given time t0 as a model-free summary for survivorship.
For this case, 0 = P (Y > t0jT = 1)  P (Y > t0jT = 0) and ^ = S^1(t0)  S^0(t0); where S^j() is the
Kaplan-Meier estimator of the survival function of Y in group j; j = 0; 1. For this case, ^   0
= n 1
nX
i=1
"
 Ti

S^1(t0)
Z t0
0
dM^i1(s)PN
j=1 I(
~Yj > s)Tj
+
1  Ti
1   S^0(t0)
Z t0
0
dM^i0(s)PN
j=1 I(
~Yj > s)(1  Tj)
#
+op(
1p
n
);
where
M^ij(s) = I( ~Yi 6 s)i  
Z s
0
I( ~Yj > u)d
n
Ti^1(u) + (1  Ti)^0(u)
o
;
and ^j() is the Nelson-Alan estimator for the cumulative hazard function of Y in group j (Flemming &
Harrington 1991).
To summarize a global survivorship beyond using t-year survival rates, one may use the mean survival
time. Unfortunately, in the presence of censoring, such a measure cannot be estimated well. An alternative
is to use the so-called restricted mean survival time, that is, the area under the survival function up to time
http://biostats.bepress.com/harvardbiostat/paper132
On the covariate-adjusted estimation for the treatment difference 9
point t0. The corresponding consistent estimator is the area under the Kaplan-Meier curve. For this case,
0 = E(Y ^ t0jT = 1)  E(Y ^ t0jT = 0) and
^ =
Z t0
0
S^1(s)ds 
Z t0
0
S^0(s)ds;
For this case, ^   0
= n 1
nX
i=1
"
 Ti

Z t0
0
( R t0
s
S^1(t)dtPN
j=1 I(
~Yj > s)Tj
)
dM^i1(s) +
1  Ti
1  
Z t0
0
( R t0
s
S^0(t)dtPN
j=1 I(
~Yj > s)(1  Tj)
)
dM^i0(s)
#
+op(
1p
n
).
4. A SIMULATION STUDY
We conducted an extensive simulation study to examine the finite sample performance of the new esti-
mates ^cv() and ^opt for 0. Specifically, under various practical settings, we investigate whether V^cv()
estimates the true variance of ^cv() well. Furthermore, we examine the finite sample properties for the
interval estimation procedure based on the optimal ^opt. For all cases studied, we find that the proposed
estimation procedure performs well. Moreover, although V^lasso() in (2.2) is an asymptotically consistent
estimator for the variance of ^cv(), we find that it can be substantially smaller than the true variance.
As a specific example in our numerical study, we consider the following models for generating the
data:
Y =
20X
j=1
j
20
Z[j] +N(0; 1); for T = 0; and
Y = 1 +
20X
j=1
j
20
Z[j] +N(0; 1); for T = 1;
where (Z[1];    ; Z[100])0 is generated from the standard multivariate normal distribution. Here, n =
200; p = 100 and the group mean difference 0 = 1. For each generated data set, the 20-fold cross val-
idation is used to calculate ^cv() and V^cv() over a sequence of tuning parameters f1; 2;    ; 100g;
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where 1 is chosen such that ^(1) = 0 for all the simulated data sets, f1;    ; 99g is a sequence of
values evenly decreasing from 1 to 99 = 10 31 on the log scale, and 100 = 0. In figure 1(a), we
present the empirical average for V^cv() (blue curve) and the empirical variance of ^cv() (red curve)
based on 5000 replications, where the x-axis is the order of those 100  values. The empirical average
of V^lasso() is also presented (green curve). The figure shows on average V^cv() is almost identical to
the empirical variance of ^cv(). On the other hand, V^lasso() without using cross validation tends to
substantially under estimate the true variance.
In this same set of simulation, we also generate a binary response Y from the following logistic
regression model
P(Y = 1jT = 1) = expf1 +
P20
j=1
j
20Z[j]g
1 + expf1 +P20j=1 j20Z[j]g ; and
P(Y = 1jT = 0) = expf
P20
j=1
j
20Z[j]g
1 + expfP20j=1 j20Z[j]g .
Here, n = 200; p = 100 and the log(odds ratio) is the parameter of interest. The results on variance
estimates are shown in Figure 1(b). Again, the variance estimator V^cv() behaves well, but not V^lasso().
Lastly, we simulate the survival time from the following Cox regression model
Y = 0 exp
8<:1 +
20X
j=1
j
20
Z[j]
9=; ; for T = 1; and
Y = 0 exp
8<:
20X
j=1
j
20
Z[j]
9=; ; for T = 0;
where 0 follows the unit exponential distribution. The censoring distribution is generated from U(0; 3);
which yields approximately 50% of censoring. Here, n = 200; p = 100 and the difference in mean sur-
vival time truncated at t0 = 2.2 is the parameter of interest. The simulation results on variance estimates
are shown in Figure 1(c). The V^cv() curve has almost no any meaningful difference from the “true”
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variance curve of ^cv(). Note that for the above three sets of simulation, we also find that ^cv() almost
has no bias for estimating 0 as expected.
We also examine the performance of the optimal estimator ^opt = ^cv(^), where ^ is chosen to be the
minimizer of V^cv();  2 f1;    ; 100g. First, with the above 5000 simulated data, one can obtain the
empirical variances of ^cv(). Let 0 be the minimizer of the curve of such empirical variances over .
Then, for each set of the above simulation, we generated 5000 0.95 confidence intervals based on ^opt and
V^opt = V^cv(^). We compute the corresponding empirical coverage level and the length. For comparisons,
we also obtain those values based on the simple estimator ^ and its variance estimate V^ , and also based on
the cross validation estimation procedure with 0. The results are summarized in Table 1. The coverage
levels for ^opt are close to the nominal counterparts and the interval lengths are almost identical to those
for the estimate with the true optimal 0. On the other hand, the simple estimate ^ tends to have substantial
wider interval estimates that ^opt.
For all cases studied, the estimate ^opt is almost unbiased and can substantially improve the efficiency
of the simple estimate ^ for the overall treatment difference in terms of narrowing the length of the con-
fidence interval of 0. Furthermore, the variability in ^ is almost negligible in making inference for 0
based on ^cv(^).
5. AN EXAMPLE
We illustrate the new proposal with the data from a clinical trial to compare D-penicillmain and placebo for
patients with primary biliary cirrhosis (PBC) of liver (Therneau & Grambsch 2000). The primary endpoint
is the time to death. The trial was conducted between 1974 and 1984. For illustration, we use the difference
of two restricted mean survival times up to t0 = 3650 (days) as the primary parameter 0 of interest.
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Moreover, we consider 18 baseline covariates for augmentation: gender, stage (1, 2, 3, and 4), presence of
ascites, edema, hepatomegaly or enlarged liver, blood vessel malformations in the skin, log-transformed
age, serum albumin, alkaline phosphotase, aspartate aminotransferase, serum bilirubin, serum cholesterol,
urine copper, platelet count, standardized blood clotting time and triglycerides. There are 276 patients with
complete covariate information (136 and 140 in control and D-penicillmain arms, respectively). The data
used in our analysis are given in the Appendix D.1 of Flemming &Harrington (1991). Figure 2(a) provides
the Kaplan-Meier curves for the two treatment groups. The simple two sample estimate ^ is 115.2 (days)
with an estimated standard error V^ of 156.6 (days). The corresponding 95% confidence interval for the
difference is (-191.8, 422.1) (days). The optimal estimate ^opt augmented additively with the above 18
coavariates is 106.3 with an estimated standard error V^opt of 121.4. These estimates were obtained via
a 23-fold cross validation (Note that 276 = 23  12) described in Section 2. The corresponding 95%
confidence interval is (-131.8, 344.4).
To examine how robust the new proposal is with respect to different augmentations. We consider a
case which includes the above 18 covariates, but also their quadratic terms as well as all their two-way
interactions. The dimension of Z is 178 for this case. The resulting optimal ^opt is 110.1 with an estimated
standard error of 122.6. Note the resulting estimates are amazingly close to those based on the augmented
procedure with 18 covariates only.
To examine the advantage of using the cross validation for the standard error estimation, in Figure 2(b),
we plot V^cv() and V^lasso() over the order of 100 ’s, which were generated using the same approach
as in Section 4. Note that V^lasso() is substantially smaller than V^cv(); especially when  approaches to
0, that is, there is no penalty for the L2 loss function. For ^opt; V^lasso is about 20% smaller than its cross
validated counterpart.
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It has been shown via numerical studies that the ZTD performs well via the standard stepwise regres-
sion by ignoring the sampling variation of the estimated weights when the dimension ofZ is not large with
respect to n. However, it is not clear how the ZTD augmentation performs with a relatively high dimen-
sional covariate vector Z. It would be interesting to compare the ZTD and the new proposal with the PBC
data. To this end, we implement ZTD augmentation procedure using (1) baseline covariates (p = 18); (2)
baseline covariates and their quadratic transformations as well as all their two-way interactions (p = 178);
and (3) only five baseline covariates: edema and log-transformed age, serum albumin, serum bilirubin and
standardized blood clotting time, which were selected in building a multivariate Cox regression model to
predict the patient’s survival by Therneau & Grambsch (2000). Note that the ZTD procedure augments
the following estimating equations for 0
nX
i=1
(1  Ti) ~i
K^0( ~Yi ^ t0)
[ ~Yi ^ t0   at0 ] = 0;
nX
i=1
Ti ~i
K^1( ~Yi ^ t0)
[ ~Yi ^ t0   at0   ] = 0;
where at0 is the restricted mean for the comparator and  is the treatment difference, ~i = I(Yi^t0 < Ci)
and K^j() is the Kaplan-Meier estimate for the survival function of censoring time C in group T = j; j =
0; 1. In Table 2, we present the resulting ZDT point estimates and their corresponding standard error
estimates for the above three cases. We used the standard forward stepwise regression procedure to select
the augmentation covariates with the entry Type I error rate of 0.10 (Zhang et al., 2008; Zhang & Gilbert,
2010). It appears that using the entire data set for selecting covariates and making inferences about 0 may
introduce nontrivial bias and an overly optimistic standard error estimate when p is large. On the other
hand, the new procedure does not lose efficiency and yields similar result as ZTD procedure when p is
small.
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6. REMARKS
The new proposal performs well even when the dimension of the covariates involved for augmentation is
not large. The new estimation procedure may be implemented for improving estimation precision regard-
less of the marginal distributions of the covariate vectors between two treatment groups being balanced.
On the other hand, to avoid post ad hoc analysis, we strongly recommend that the investigators prespecify
the set of all potential covariates for adjustment in the protocol or the statistical analysis plan before the
data from the clinical study are unblinded.
The stratified estimation procedure for the treatment difference is also commonly used for improving
the estimation precision using baseline covariate information. Specifically, we divide the population into
K strata based on baseline variables, denoted by fZ 2 B1g;    ; fZ 2 BKg; the stratified estimator is
^str =
PK
k=1 ^kwkPK
k=1 wk
;
where ^k and wk are corresponding simple two sample estimator for the treatment difference and the
weight for the kth stratum, k = 1;    ;K. In general, the underlying treatment effect may vary across
strata and consequently the stratified estimator may not converge to 0. If 0 is the mean difference be-
tween two groups and wk is the size of the kth stratum, ^str is a consistent estimator for 0. Like the
ANCOVA, the stratified estimation procedure may be problematic. On the other hand, one may use the
indicators fI(Z 2 B1);    ; I(Z 2 BK)g0 to augment ^ to increase the precision for estimating the
treatment difference 0.
In this paper we follow the novel approach taken, for example, by Zhang et al. (2008) for augmenting
the simple two sample estimator, but present a systematic, practical procedure for choosing covariates
for making valid inferences about the overall treatment difference. When p is large, there are several ad-
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vantages over other approaches for augmenting ^ with covariates. Firstly, it avoids the complex variable
selection step in two arms separately as proposed in Zhang et al. (2008). Secondly, compared with other
variable selection methods such as the stepwise regression, the lasso method directly controls the variabil-
ity of ^; which is important to ensure the validity of the statistical inference for the treatment difference.
When  increases from 0 to +1, the resulting estimator varies from the fully augmented estimator us-
ing all the components of Zi to ^. The lasso procedure also possesses superior computational efficiency
with high dimensional covariates to alternatives. Lastly, since the ZTD estimator can also be viewed as a
generalized method of moment estimator with

   ^0
n 1
Pn
i=1 i

 0
as moment conditions (Hall 2005), the cross validation method introduced here may be extended to a
much broader context than the current setting.
It is important to note that if a permuted block treatment allocation rule is used for assigning patients
to the two treatment groups, the augmentation method proposed in the paper can be easily modified. For
instance, for the K-fold cross validation process, one may choose the sets fDk; k = 1;    ;Kg so that
each permuted block would not be in different sets.
For assigning patients to the treatment groups, a stratified random treatment allocation rule is also
often utilized to ensure a certain level of balance between the two groups in each stratum. For this case,
a weighted average 0 of the treatment differences k0 with weight wk; k = 1;    ;K; across K strata
may be the parameter of interest for quantifying an overall treatment contrast. Let ^k be the simple two
sample estimator for k0 and w^k be the corresponding empirical weight for wk. Then the weight average
^ =
P
k w^k^k=
P
k w^k is the simple estimator for 0. For the kth stratum, one may use the same approach
as discussed in this paper to augment ^k; let the resulting optimal estimator be denoted by ^opt;k. Then we
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can use the weighted average
P
k w^k^opt;k=
P
k w^k to estimate 0. On the other hand, for the case with
the dynamic treatment allocation rules (see, for example, (Pocock & Simon 1975)), it is not clear how
to obtain a valid variance estimate even for the simple two sample estimator ^ (Shao et al. 2010). How
to extend the augmentation procedure to cases with more complicated treatment allocation rule warrants
further research.
7. APPENDIX
7.1 Appendix A: Asymptotical Equivalence Between ZTD and ANCOVA.
When the group mean is the parameter of interest, the naive estimator for 0 can viewed as the root of the
estimating equation
nX
i=1

Ti
1  Ti

S0(; a; Yi; Ti) =
nX
i=1

Ti
1  Ti

(Yi   a  Ti) = 0;
where a = E(Y jT = 0) is a nuisance parameter. In the ZTD augmentation procedure, one may augment
this simple estimating equation via following steps
 Obtain the initial estimator 
^
a^

=
1
n
nX
i=1
 
(Ti )Yi
(1 )
(1 Ti)Yi
1 
!
from the original estimating equation
 Obtain ^1 and ^00 by minimizing the objective function
nX
i=1
TifS0(^; a^; Yi; Ti)  01Zig2
and
nX
i=1
(1  Ti)fS0(^; a^; Yi; Ti)  00Zig2
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respectively. In other words, using ^0jZ to approximate EfS0(0; a0;Y; T )jZ; T = jg.
 Solve the augmented estimating equations
nX
i=1

Ti
1  Ti

S0(; a; Yi; Ti) 
nX
i=1
(Ti   )

^01Zi
^00Zi

= 0
to obtain the ZTD estimator.
The resulting ZTD estimator is always asymptotically more efficient than the naive counterpart and a
simple sandwich variance estimator can be used to consistently estimate the variance of the new estima-
tor. It has been shown that ZTD estimator is asymptotically the most efficient one from the class of the
estimators
A =
(
^ = ^   0
(
n 1
nX
i=1
(Ti   )Zi
(1  )
)   2 Rp
)
;
whose members are all consistent for 0 and asymptotically normal. Since
^   0 = 1
n
nX
i=1

(Ti   )Yi
(1  )   0

;
the optimal weight minimizing the variance of
^   0 1
n
nX
i=1
(Ti   )Zi
(1  )
is simply
"
E

(Ti   )Zi
(1  )

2# 1
E

(Ti   )Zi
(1  )

(Ti   )Yi
(1  )   0

=[E(Z
2i )]
 1E(ZiYi) = 0
Therefore, ZTD estimator is asymptotically equivalent to the commonly used ANCOVA estimator. This
equivalence is noted in Tsiatis et al. (2008).
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7.2 Appendix B: An Example on the Potential Bias of ZTD Procedure
In this section we show via an example that if we estimate the weights  with the entire data set and then
construct ^lasso(0) and ZTD estimator with the same data set, the resulting estimation procedure can be
substantially biased. To this end, we consider the following models to generate the data:
Y =
10X
j=1
1  Z2[j]
2
 
20X
j=1
j
20
Z[j] +N(0; 1); for T = 0; and
Y =
10X
j=1
Z2[j]   1
2
+
20X
j=1
j
20
Z[j] +N(0; 1); for T = 1;
where (Z[1];    ; Z[20])0 is the 20-dimensional standard multivariate normal. We let the total sample size
be 200 with 1:1 random allocations. Here, the true parameter 0 = 0. We construct ^lasso(0) and the ZTD
estimator. Based on 5000 simulated data sets from the above model, we obtain the average bias and the
standard error. The empirical bias of ^lasso(0) is -0.09, which is 24% of the empirical standard error. The
ZTD estimator is slightly more biased than ^lasso(0) with an empirical bias of -0.12, 31% of its empirical
standard error.
7.3 Appendix C: Justification of the cross validation based variance estimator for ^cv()
To justify the cross validation based variance estimator, first consider the expansion
^cv() =
(
^   00
 
n 1
nX
i=1
i
!)
  n 1
nX
i=1
f^( i)()  0g0i.
The variance of ^cv() can be expressed as V11 + V22   2V12, where
V11 = E
(
^   00
 
n 1
nX
i=1
i
!)2
;
V22 =
1
n2
E
"
nX
i=1
f^( i)()  0g0i
#2
;
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and
V12 =
1
n
E
"(
^   00
 
n 1
nX
i=1
i
!)
nX
i=1
f^( i)()  0g0i
#
.
Firstly
V12 =
1
n2
E
"
nX
i=1
(i(^)  00i)
nX
i=1
f^( i)()  0g0i
#
 1
n2
X
i6=j
E

(i(^)  00i)f^( j)()  0g0

Ej +
1
n2
nX
i=1
E

(i(^)  00i)f^( i)()  0g0i

 1
n2
nX
i=1
Ef^( i)()  0g0E [(i(^)  00i)i]  0.
Therefore, the variance of the augmented estimator ^cv() is approximately
V11 + V22
=
1
n

Ef(i(^)  00i)2g+ Ef(^( i)()  0)0ig2

+
(n  1)
n
E[01f^( 1)()  0g02f^( 2)()  0g]
V^cv() + (n  1)
n
E[01^( 1)()
0
2^( 2)()].
In our experience, d() = E[01^( 1)()
0
2^( 2)()] = O(n
 2) is very small compared with V^cv() =
O(n 1) and is negligible, when  is not close zero . Therefore, in general, V^cv() serves as a satisfactory
estimator for the variance of ^cv(). For small , to explicitly estimate d(); the covariance between
01^( 1)() and 
0
2^( 2)(), one may use
d^() =
2(K2   1)
n(n  1)K
X
16i<j6n
0i

K   1
K
^( j)()  ^()

0j

K   1
K
^( i)()  ^()

(7.1)
as an ad-hoc jackknife-type estimator, where ^() is the lasso solution based on the entire data set. To
justify the approximation, first note that when  is close to zero,
^()  0 
nX
i=1
i and ^( i)()  0  K
K   1
X
i=2Dki
i
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where i is the mean zero influence function from the ith observation for ^(). Therefore,
d() = E[01^( 1)()
0
2^( 2)()] 

1  1
K2

E[012
0
21];
which can be approximated by d^() and one may use V^cv() + (n  1)d^()=n as the variance estimator
for the augmented estimator. Note that the difference between V^cv and its modified version appears to be
negligible in all the numerical studies presented in the paper.
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Fig. 1. Comparing various estimates for ^cv() at f1;    ; 100g: the empirical variance of ^cv() (red curve);
V^cv() (blue curve); V^lasso() (green curve)
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(a) Estimated survival functions of D-penicillmain (red)
and placebo arms (black)
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(b) V^cv() (black) vs. V^lasso() (red)
Fig. 2. Analysis results for primary biliary cirrhosis data
Hosted by The Berkeley Electronic Press
24 L. TIAN ET AL.
Table 1. The empirical coverage levels and lengths for the 0.95 interval estimation procedure based on ^opt and V^opt
(EAL: empirical length; ECL: empirical coverage level)
^opt ^ ^cv(0)
Response EAL ECL EAL ECL EAL ECL
Continuous 0.644 94.4% 1.578 95.4% 0.653 94.4%
Binary 0.946 94.7% 1.136 94.7% 0.954 94.9%
Survival 0.476 93.8% 0.626 94.4% 0.479 94.1%
Table 2. Comparisons between the new and ZTD estimate with the data from the Mayo Clinic Primary Biliary Cir-
rhosis clinical trial (SE: estimated standard error)
The new optimal procedure ZTD
p Estimate SE Estimate SE
5 92.0 121.5 96.3 119.4
18 106.3 121.4 126.4 111.7
178 110.1 122.6 65.3 114.6
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